To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma

The primary objective of this study was to evaluate the safety and tolerability of SG2918 in patients with relapsed/refractory multiple myeloma.

Trial Details

NCT ID
NCT07454187
Phase
PHASE1 / PHASE2
Sponsor
Hangzhou Sumgen Biotech Co., Ltd.
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • SG2918
Locations (sample)
  • Zhengzhou, Henan, China|34.75778,113.64861
  • Suzhou, Jiangsu, China|31.30408,120.59538
  • Xi’an, Shanxi, China|35.99785,113.52486
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Age ≥ 18 years and ≤ 80 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.
  • Life expectancy ≥ 3 months.
  • Documented diagnosis of multiple myeloma.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →